Alexion

News

Alexion's new CFO promises to put cash to good use

After announcing the shock departure of Alexion's chief executive and chief financial officer yesterday, the company's chairman Leonard Bell quickly named David Brennan, ex-AstraZeneca chie

Articles

Alexion: aiming to break new ground in ultra-rare therapies

Martin Mackay, head of R&D at Alexion, talks to pharmaphorum about the company's research pipeline for severe and ultra-rare diseases.

News

Kanuma approval adds to Alexion rare disease roster

Alexion has gained FDA approval for Kanuma, its treatment for the rare disease lysosomal acid lipase (LAL) deficiency.

News

Rare disease drug Strensiq too expensive, says NICE

Alexion's new rare disease treatment Strensiq has been rejected by England's health watchdog NICE in draft guidance.

News

Alexion must ‘explain’ high cost of Soliris, says NICE

NICE has concluded that orphan drug Soliris is highly effective in treating rare disease aHUS – but says it won't approve the drug yet, asking pharma company Alexion to first 'explain' how

Alexion's new CFO promises to put cash to good use

Alexion: aiming to break new ground in ultra-rare therapies

Kanuma approval adds to Alexion rare disease roster

Rare disease drug Strensiq too expensive, says NICE

Alexion must ‘explain’ high cost of Soliris, says NICE

ASH: AstraZeneca's dual-wielding CAR-T shows promise

How to meet your physicians where they are online

Alexion

Editor's Picks